You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
New hope for hair loss
- Thread starter otis
- Start date
the_newsoul
New Member
- Reaction score
- 0
if we do something with this is blocking receptor 2 (GPR44), not blocking prostaglandins or PGD2
Nashville Hairline
Experienced Member
- Reaction score
- 9
Excellent news. Better treatments are coming, I can feel it!
MarkMaybeakook
Member
- Reaction score
- 0
Nashville Hairline said:Excellent news. Better treatments are coming, I can feel it!
Just hang on another 5 years, just 5 more years baby!!!!
MarkMaybeakook said:Nashville Hairline said:Excellent news. Better treatments are coming, I can feel it!
Just hang on another 5 years, just 5 more years baby!!!!
noooo they are on phase 2
:agree:
bornthisway
Established Member
- Reaction score
- 9
Regarding setipiprant...
ALLSCHWIL/BASEL, SWITZERLAND - 02 April 2012 - Actelion Ltd (SIX: ATLN) announced today that the company will re-direct its development efforts in the anti-inflammatory area, focusing on a potent follow-up CRTH2 antagonist currently in Phase I clinical development.
Two recently concluded studies with the first orally-active CRTH2 antagonist, setipiprant, in asthma (Phase IIb) and seasonal allergic rhinitis (Phase III profiling) did not confirm efficacy findings made in earlier studies. Accordingly, clinical development with this well-tolerated agent in these indications is being discontinued.
By focusing on the more potent follow-up compound, Actelion expects to further develop the understanding of the CRTH2 mechanism as a potential anti-inflammatory mode of action in allergic indications.
http://www1.actelion.com/en/our-company ... Id=1598979
ALLSCHWIL/BASEL, SWITZERLAND - 02 April 2012 - Actelion Ltd (SIX: ATLN) announced today that the company will re-direct its development efforts in the anti-inflammatory area, focusing on a potent follow-up CRTH2 antagonist currently in Phase I clinical development.
Two recently concluded studies with the first orally-active CRTH2 antagonist, setipiprant, in asthma (Phase IIb) and seasonal allergic rhinitis (Phase III profiling) did not confirm efficacy findings made in earlier studies. Accordingly, clinical development with this well-tolerated agent in these indications is being discontinued.
By focusing on the more potent follow-up compound, Actelion expects to further develop the understanding of the CRTH2 mechanism as a potential anti-inflammatory mode of action in allergic indications.
http://www1.actelion.com/en/our-company ... Id=1598979